Serum levels of Interleukin-15 and Interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma

Cytokine

Volumn 37, Issue 2, 2007, Pages 171-175

  Pappa, C ^a   Miyakis, S ^b   Tsirakis, G ^a   Sfiridaki, A ^c   Alegakis, A ^a   Kafousi, M ^a   Stathopoulos, E N ^a   Alexandrakis, M G ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Venizelion General Hospital   (Greece)

Author keywords

Angiogenesis; Interleukin 10; Interleukin 15; Multiple myeloma; PCNA

Indexed keywords

CYCLINE; INTERLEUKIN 10; INTERLEUKIN 15;

ARTICLE; CANCER GROWTH; CANCER STAGING; CELL KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-15; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; STATISTICS;

EID: 34247869006     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.02.022     Document Type: Article

References (26)

1. Treon S.P., and Anderson K.C. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 5 (1998) 42-48
2. Otsuki T., Yamada O., Yata K., Sakaguchi H., Kurebayashi J., Yawata Y., et al. Expression and production of interleukin 10 in human myeloma cell lines. Br J Haematol 111 (2000) 835-842
3. Tinhofer I., Marschitz I., Henn T., Egle A., and Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 95 (2000) 610-618
4. Merico F., Bergui L., Gregoretti M.G., Ghia P., Aimo G., Lindley I.J., et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 92 (1993) 27-31
5. Hawley R.G., and Berger L.C. Growth control mechanisms in multiple myeloma. Leuk Lymphoma 29 (1998) 465-475
6. Trentin L., Cerutti A., Zambello R., Sancretta R., Tassinari C., Facco M., et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 87 (1996) 3327-3335
7. Hjorth-Hansen H., Waage A., and Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 106 (1999) 28-34
8. Kakumu S., Okumura A., Ishikawa T., Yano M., Enomoto A., Nishimura H., et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 109 (1997) 458-463
9. Otsuki T., Yata K., Sakaguchi H., Uno M., Fujii T., Wada H., et al. IL-10 in myeloma cells. Leuk Lymphoma 43 (2002) 969-974
10. Armitage R.J., Macduff B.M., Eisenman J., Paxton R., and Grabstein K.H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154 (1995) 483-490
11. Zambello R., Facco M., Trentin L., Sancetta R., Tassinari C., Perin A., et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 89 (1997) 201-211
12. Meazza R., Basso S., Gaggero A., Detotero D., Trentin L., Pereno R., et al. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor beta/gamma. Int J Cancer 78 (1998) 189-195
13. Mazur G., Bogunia-Kubik K., Wrobel T., Karabon L., Polak M., Kuliczkowski K., et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96 (2005) 241-246
14. Lu Z.Y., Zhang X.G., Rodriguez C., Wijdenes J., Gu Z.J., Morel-Fournier B., et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 85 (1995) 2521-2527
15. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Dambaki K., Niniraki M., and Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 27 (2004) 8-13
16. Budke H., Orazi A., Neiman R.S., Cattoretti G., John K., and Barberis M. Assessment of cell proliferation in paraffin sections of normal bone marrow by the monoclonal antibodies Ki-67 and PCNA. Mod Pathol 7 (1994) 860-866
17. Skopelitou A., Tselenis S., Theocharis S., Agnantis N., Tsenga A., Elemenoglou J., et al. Expression of proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in multiple myeloma. Anticancer Res 14 (1994) 787-792
18. Alexandrakis M.G., Passam F.H., Pappa C.A., Dambaki C., Sfakiotaki G., Alegakis A.K., et al. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity. Int J Immunopathol Pharmacol 17 (2004) 49-56
19. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
20. Waldmann T., Tagaya Y., and Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 16 (1998) 205-226
21. Kuniyasu H., Ohmori H., Sasaki T., Sasahira T., Yoshida K., Kitadai Y., et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9 (2003) 4802-4810
22. Mrozek E., Anderson P., and Caligiuri M.A. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87 (1996) 2632-2640
23. Oppenheimer-Marks N., Brezinschek R.I., Mohamadzadeh M., Vita R., and Lipsky P.E. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J Clin Invest 101 (1998) 1261-1272
24. Urbanska-Rys H., Wiersbowska A., Stepien H., and Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 11 (2000) 443-451
25. Hall P.A., Levison D.A., Woods A.L., Yu C.C., Kellock D.B., Watkins J.A., et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162 (1990) 285-294
26. Chaidos A.I., Bai M.C., Kamina S.A., Kanavaros P.E., Agnantis N.J., and Bourantas K.L. Incidence of apoptosis and cell proliferation in multiple myeloma: correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor. Eur J Haematol 69 (2002) 90-94